Barnett Valerie 4

What Happened
Valerie Barnett, Chief Legal Officer of Cytek Biosciences (CTKB), had a group of Restricted Stock Units (RSUs) convert into 24,295 shares on May 18, 2026 (reported on Form 4 filed May 20, 2026). To satisfy tax withholding on the vesting, 8,719 shares were withheld/surrendered (disposed) at an indicated withholding value of $3.55 per share, totaling $30,953. The filings show the RSU-to-share conversion as derivative exercises (code M) and the withholding as tax withholding (code F).

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (timely within typical reporting window).
• Shares converted (RSU vesting): 24,295 shares (2,454 + 5,156 + 7,250 + 9,435).
• Shares withheld for taxes: 8,719 shares (881 + 1,850 + 2,602 + 3,386) at $3.55/share = $30,953 total.
• Net increase in shares held after the transactions: +15,576 shares (24,295 converted − 8,719 withheld).
• Transaction codes: M = exercise/conversion of derivative (RSU settlement); F = shares surrendered to satisfy tax withholding.
• Footnotes: RSUs represent contingent rights to one share each (F1); withheld shares were surrendered to the issuer to satisfy taxes (F2); vesting schedules described in F3–F6 (multi‑year vesting on May/Aug/Nov/Mar dates).

Context
This was an RSU vesting and tax-withholding event — not an open‑market sale or purchase. Surrendering shares to cover tax obligations is routine and does not necessarily signal a change in insider sentiment. For retail investors, the notable outcome is a net increase of 15,576 shares held by the CLO following the vesting.